Get the Stockscreener App
22.61
0.85%
0.19
After Hours:
22.61
Innoviva Inc stock is traded at $22.61, with a volume of 564.65K.
It is up +0.85% in the last 24 hours and up +2.91% over the past month.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
See More
Previous Close:
$22.42
Open:
$22.99
24h Volume:
564.65K
Relative Volume:
0.74
Market Cap:
$1.67B
Revenue:
$434.49M
Net Income/Loss:
$504.34M
P/E Ratio:
3.7597
EPS:
6.0138
Net Cash Flow:
$181.97M
1W Performance:
+0.31%
1M Performance:
+2.91%
6M Performance:
+13.50%
1Y Performance:
+3.72%
1-Day Range:
$22.37
$23.00
1-Week Range:
$22.33
$23.37
52-Week Range:
$16.52
$25.14
Innoviva Inc Stock (INVA) Company Profile
Name
Innoviva Inc
Sector
Industry
Phone
(650) 238-9600
Address
1350 OLD BAYSHORE HIGHWAY, BURLINGAME
Compare INVA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
22.61 | 1.65B | 434.49M | 504.34M | 181.97M | 6.0138 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Initiated | BTIG Research | Buy |
| Sep-30-25 | Initiated | Goldman | Sell |
| Aug-11-25 | Initiated | Oppenheimer | Outperform |
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-20-22 | Initiated | Goldman | Neutral |
| Nov-20-17 | Initiated | Deutsche Bank | Hold |
View All
Innoviva Inc Stock (INVA) Latest News
Responsive Playbooks and the INVA Inflection - Stock Traders Daily
INVA Q1 2026 Earnings: EPS Falls Far Short of Estimates, Stock DeclinesRevenue Per Share - newsline.com
Innoviva Inc. (INVA) Q1 2026 Earnings: Significant EPS Miss Despite Positive Stock ReactionQuarterly Earnings Report - newsline.com
Innoviva stock rises to $23.00 amid constructive trends and renewed buyer momentum - Traders Union
INVA Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; Stock Rises 0.94%Final Results - newsline.com
Innoviva (INVA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary - Quartr
Understanding the Setup: (INVA) and Scalable Risk - Stock Traders Daily
Innoviva Board Shift And New Treatment Launch Create Valuation Question - Sahm
Innoviva, Inc. to Present at Investor Conferences - geneonline.com
Innoviva to Participate in Upcoming Investor Conferences - New Castle News
INVA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $46 - GuruFocus
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More - AOL.com
Has Innoviva Successfully Pivoted Beyond its Royalty Roots - Kavout
INVA Q1 2026 Earnings: Significant EPS Miss Drives Stock DeclineFull Year Guidance - The Legal Advocate
INVA Q1 2026 Earnings: EPS Miss Triggers 2% Stock DeclineDividend Cut Risk - The Legal Advocate
Innoviva (INVA) Holds Near Key Support on Light Volume as Biotech Sector Navigates UncertaintyBullish Pattern Stocks - The Legal Advocate
Analysts Offer Insights on Healthcare Companies: Spectral AI (MDAI), NeOnc Technologies Holdings, Inc. (NTHI) and Innoviva (INVA) - The Globe and Mail
Innoviva (INVA) Q1 2026 Earnings: EPS Misses Estimates by Over 112%, Stock DeclinesEarnings Call Highlights - newsline.com
INVA Reiterates by BTIG -- Price Target Maintained at $42 - GuruFocus
Innoviva Inc. (INVA) Gains Ground Amid Sector DynamicsPost-Earnings Moves - The Legal Advocate
INNOVIVA INC (NASDAQ:INVA) Scores as a Value Stock with Strong Fundamentals - ChartMill
The Technical Signals Behind (INVA) That Institutions Follow - Stock Traders Daily
INVA Q1 2026 Earnings: Significant EPS Miss Amid Lack of Revenue DisclosureOne-Time Loss Impact - Newser
INVA Q1 2026 Earnings: EPS Misses Estimates Despite Modest Stock GainOpen Signal Network - Newser
Innoviva (INVA) CFO adds ESPP shares and uses stock to pay taxes - Stock Titan
Innoviva (INVA) CEO logs ESPP share grant and tax withholding on Form 4 - Stock Titan
Innoviva (NASDAQ: INVA) CAO has shares withheld to cover tax obligations - Stock Titan
Innoviva (INVA) Q1 2026 Earnings Miss by Significant: Key TakeawaysHot Momentum Watchlist - Newser
Innoviva Appoints Josephine Linden to Strengthen Board Oversight - TipRanks
Innoviva Board Shakeup Puts Governance And Valuation In Focus - Sahm
Innoviva (INVA) director receives RSU and stock option grants as board compensation - Stock Titan
Innoviva (INVA) director Josephine Linden files Form 3 showing no share ownership - Stock Titan
Innoviva announces board changes and appoints Josephine Linden as director - Investing.com Nigeria
Innoviva (INVA) refreshes board as two directors resign, adds Josephine Linden - Stock Titan
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - Sahm
Armata Pharmaceuticals (ARMP) Q1 2026: EPS -3.16 Misses Est. -0. - GuruFocus
Precision Trading with Innoviva Inc. (INVA) Risk Zones - Stock Traders Daily
Armata Pharmaceuticals (ARMP) now 82.7% owned by Innoviva after new loan - Stock Titan
Armata (NYSE: ARMP) loss, debt surge and Phase 3 bacteremia trial plan - Stock Titan
Armata Pharma Entered Into Secured Credit Agreement With Innoviva for $25 M Maturing in 2029 >ARMP - Moomoo
Press Release: Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - Moomoo
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress - Quantisnow
TradingKey - TradingKey
Why are smart money investors paying attention to Innoviva (INVA)? (Mini Rally) 2026-05-11Professional Trade Ideas - newser.com
Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness? - Yahoo Finance
What Innoviva (INVA)'s Profit Rebound and ESOP Share Filing Means For Shareholders - simplywall.st
Innoviva Inc Emerges as Top Small Cap Value Stock with High Royalty Revenues - HarianBasis.co
Innoviva Inc Stock (INVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):